CompuMed (OTCMKTS:CMPD) Stock Price Up 3.8% – Here’s Why

CompuMed Inc. (OTCMKTS:CMPDGet Free Report)’s share price rose 3.8% during trading on Tuesday . The company traded as high as $6.95 and last traded at $6.95. Approximately 3,020 shares changed hands during trading, an increase of 3% from the average daily volume of 2,940 shares. The stock had previously closed at $6.6962.

CompuMed Price Performance

The firm has a market capitalization of $9.24 million, a PE ratio of -138.97 and a beta of -0.30. The company has a debt-to-equity ratio of 0.16, a current ratio of 2.04 and a quick ratio of 2.01. The firm has a 50-day simple moving average of $5.20 and a 200-day simple moving average of $4.15.

CompuMed (OTCMKTS:CMPDGet Free Report) last issued its quarterly earnings results on Friday, February 13th. The company reported $0.02 earnings per share for the quarter. CompuMed had a negative net margin of 0.78% and a negative return on equity of 1.88%. The business had revenue of $2.10 million for the quarter.

CompuMed Company Profile

(Get Free Report)

CompuMed, Inc, an enterprise telemedicine solutions company, provides clinical care services for patients and medical facilities. It offers telecardiology and teleradiology services that provide real-time access to U.S. Board-Certified specialists through cloud-based technology and integrated medical devices to medical facilities worldwide. The company also provides enterprise telemedicine solutions; a suite of telecardiology services and diagnostic exam interpretations for pediatric and adult patients, including electrocardiogram (ECG) devices, echocardiogram, ECG, vascular, holter, nuclear, and video consults; and reading, transcription, reporting, storage, and video consultations in the areas of Vscan, X-ray, ultrasound, mammography, computed tomography, magnetic resonance imaging, and radiologist video consults.

Featured Stories

Receive News & Ratings for CompuMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CompuMed and related companies with MarketBeat.com's FREE daily email newsletter.